GPCR

Structure Therapeutics Inc.

A biopharmaceutical company developing oral pills for chronic conditions, most notably a once-daily GLP-1 drug called aleniglipron aimed at obesity and type 2 diabetes. It was founded in 2016 by structural biologist Raymond Stevens alongside the drug-design firm Schrödinger, and originally went by the name ShouTi before rebranding to highlight its structure-based approach. Its stock ticker, GPCR, nods to the family of cell receptors—G protein-coupled receptors—that its medicines target.

Sponsored ADS, each representing three ordinary shares